Fortimedix has been acquired by Medtronic
Fortimedix Surgical has been successfully acquired by Medtronic (NYSE: MDT). Following the transaction, Fortimedix will operate as Medtronic Articulating Technologies.
Located at the Brightlands Chemelot Campus in Geleen, the Netherlands, Fortimedix operates a fully equipped R&D and pilot manufacturing facility that allows the seamless integration of product development and pilot manufacturing under a single roof.
Oaklins’ team in the Netherlands acted as the exclusive sell-side M&A advisor to Fortimedix in its sale to Medtronic. This transaction underscores Oaklins’ strong international track record in the medical technology sector, demonstrating their ability to unlock significant value in a rapidly evolving, innovation-driven industry. Leveraging deep sector expertise and a global network of strategic buyers, the team ensured a smooth and successful transaction process for all parties involved.
Wout Bijker
CEO, Fortimedix Surgical
Falar com a equipa da transação
Transações relacionadas
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Saber maisbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Saber maisBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Saber mais